Breaking Through the Forbidden Zone of Life! Combined Heavy Ion and Precision Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment Opens a New Chapter of Life for Patients with Advanced Pancreatic Cancer and Peritoneal Metastasis

When the "King of Cancers" Meets Its Nemesis Combination: Pancreatic cancer is known as the "King of Cancers" due to its extremely high malignancy. More concerningly, about 30%–50% of patients already have peritoneal metastasis at the time of diagnosis.

Traditional treatment methods often struggle in the face of this situation: chemotherapy drugs have difficulty penetrating the peritoneal barrier, tumor heterogeneity leads to treatment resistance, and systemic treatments come with significant side effects and poor patient tolerance.

Today, the innovative combination therapy of heavy ion treatment and precision hyperthermic intraperitoneal chemotherapy (HIPEC) is rewriting the fate of patients with advanced pancreatic cancer. Even more excitingly, Professor Yin Chunzhu, a leading domestic expert in the field of HIPEC, will personally visit our hospital on August 21, 2025, to develop individualized treatment plans and perform hyperthermic intraperitoneal chemotherapy for patients.

1.Expert Introduction

Professor Yin Chunzhu

Chief Physician, Director of the Second Department of Abdominal Surgery at Jilin Provincial Cancer Hospital. Currently serves as Vice Chairman and Secretary-General of the Sino-Korean Hyperthermo-Chemotherapy Cooperation Group, Member of the 8th Hyperthermia Group of the Chinese Medical Association Radiation Oncology Therapy Committee, Member of the CSCO Tumor Hyperthermia Expert Committee, Director of the Jilin Provincial Anti-Cancer Association, Member of the Jilin Provincial Medical Association Parenteral and Enteral Nutrition Professional Committee, Member of the Jilin Provincial Medical Association Oncology Professional Committee, and Director of the Jilin Provincial Anti-Cancer Association. With over 30 years of experience in abdominal tumor diagnosis and treatment, he specializes in the diagnosis and treatment of peritoneal cancer and the hyperthermic perfusion therapy for benign and malignant pleural and peritoneal effusions, achieving significant efficacy. He has participated in 4 research projects initiated by the Municipal Science and Technology Bureau, Provincial Health Department, and Provincial Science and Technology Department, served as the lead researcher for the Changchun Science and Technology Bureau project "Postoperative Hyperthermic Intraperitoneal Chemotherapy," contributed to the writing of "Practical Tumor Hyperthermia," and published 15 papers.

In-Depth Analysis of Treatment Principles: A 1+1>2 Synergistic Effect

Unique Advantages of Heavy Ion Therapy

1. Bragg Peak Effect: Energy is precisely concentrated on the tumor site.

2.Overcoming Radiotherapy Resistance: Maintains strong killing power even for hypoxic cancer cells.

3.Non-Invasive Precision: Protects surrounding normal tissues.

Three Major Advantages of Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

1.Hyperthermia Sensitization: High temperatures of 42–43°C can destroy cancer cell membrane structures, increasing chemotherapy drug permeability by 10–50 times.

2.Precision Strike: Intraperitoneal drug concentrations can reach 20–100 times those of intravenous chemotherapy, with reduced systemic toxicity.

3.Comprehensive Clearance: Effectively kills free cancer cells and micro-metastases in the peritoneal cavity.

Synergistic Effect of Combined Treatment: Heavy ions precisely eliminate solid tumors, while HIPEC clears free cancer cells, forming a three-dimensional treatment network.

From Evaluation to Treatment: Comprehensive Management to Build a Safe and Effective Treatment System for Patients

Our department has established a complete treatment quality control system:

Preoperative Precision Evaluation: Multidisciplinary team (MDT) consultation to clarify treatment indications.

Intraoperative Real-Time Monitoring: Temperature fluctuations ≤0.5°C, with dynamic adjustment of perfusion parameters to ensure efficacy.

Postoperative Systematic Management: Tumor marker monitoring and imaging follow-up evaluations to assess efficacy.

Department Introduction

The Minimally Invasive Tumor Treatment Center and General Surgery Department focus on the following areas:

1. Tumor Hyperthermic Perfusion Therapy: The department is equipped with a standard hyperthermic perfusion therapy room and routinely performs hyperthermic intraperitoneal chemotherapy (HIPEC) for primary or metastatic peritoneal cancer. Hyperthermic intrathoracic chemotherapy (HITOC) is used for pleural mesothelioma and malignant pleural effusions.
2. Tumor Thermal Ablation and Chemical Ablation: Routinely performs microwave/radiofrequency ablation for liver cancer, lung cancer, kidney cancer, prostate cancer, bone tumors, thyroid nodules, breast nodules, uterine fibroids, adenomyosis, and endometriosis. Chemical ablation is used for liver cancer (especially small liver cancer, diameter <3cm), thyroid cysts or benign nodules, liver and kidney cysts, and ovarian cysts/endometriotic cysts.
3. 3D printing coplanar template-guided I125 seed implantation, microwave ablation combined with bone cement成形术 for spinal and bone metastases.
4. The department routinely performs minimally invasive surgeries for gastrointestinal tumors, biliary tract diseases, acute abdomen, various abdominal wall hernias, and anorectal diseases.
   Appointment and Visit Location:

Building 7, First Floor, Inpatient Department, Heavy Ion Campus, Gansu Wuwei Cancer Hospital